KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Inventory (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Change in Inventory for 17 consecutive years, with $18.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Inventory fell 47.09% year-over-year to $18.1 million, compared with a TTM value of $116.9 million through Dec 2025, up 84.05%, and an annual FY2025 reading of $116.9 million, up 84.05% over the prior year.
  • Change in Inventory was $18.1 million for Q4 2025 at Biomarin Pharmaceutical, down from $26.3 million in the prior quarter.
  • Across five years, Change in Inventory topped out at $59.1 million in Q4 2023 and bottomed at -$18.2 million in Q3 2024.
  • Average Change in Inventory over 5 years is $22.0 million, with a median of $24.9 million recorded in 2021.
  • The sharpest move saw Change in Inventory tumbled 150.03% in 2021, then skyrocketed 1557.98% in 2023.
  • Year by year, Change in Inventory stood at $15.9 million in 2021, then skyrocketed by 156.32% to $40.8 million in 2022, then soared by 44.72% to $59.1 million in 2023, then plummeted by 42.02% to $34.3 million in 2024, then plummeted by 47.09% to $18.1 million in 2025.
  • Business Quant data shows Change in Inventory for BMRN at $18.1 million in Q4 2025, $26.3 million in Q3 2025, and $48.1 million in Q2 2025.